**SUPPLEMENTARY DATA**

|  |
| --- |
| Table 1. Univariate analysis for the prediction of mortality and/or Takotsubo recurrence. |
| Variables | **HR** | **95% CI** | **P-value** |
| Age  | 1.07 | 1.05-1.09 | <0.001 |
| Female sex | 1.17 | 0.64-2.15 | 0.601 |
| Smoking | 0.50 | 0.25-0.98 | 0.044 |
| Hypertension | 1.55 | 1.02-2.38 | 0.042 |
| Dyslipemia | 1.29 | 0.88-1.87 | 0.189 |
| Diabetes mellitus | 2.15 | 1.44-3.21 | <0.001 |
| Peripheral artery disease | 1.36 | 0.55-3.33 | 0.502 |
| Coronary artery disease | 2.14 | 1.17-3.92 | 0.013 |
| Prior stroke | 2.39 | 1.40-4.06 | 0.001 |
| Prior β-blocker therapy | 1.94 | 1.15-3.26 | 0.012 |
| COPD | 1.48 | 0.95-2.32 | 0.085 |
| History of cancer | 2.12 | 1.24-3.62 | 0.006 |
| Killip ≥ II at admission | 2.44 | 1.68-3.55 | <0.001 |
| Atrial fibrillation/flutter | 1.94 | 1.27-2.97 | 0.002 |
| Bundle brunch block | 0.52 | 0.17-1.64 | 0.264 |
| Creatinine ≥ 1.5 mg/dL | 3.02 | 1.66-5.50 | <0.001 |
| Apical vs Non apical | 1.66 | 1.05-2.61 | 0.029 |
| Trigger vs Non-trigger *Emotional Trigger* *Physical Trigger* | 0.661.31 | 0.42-1.040.84-2.06 | 0.0720.238 |
| Aspirin | 0.70 | 0.48-1.03 | 0.067 |
| P2Y12 inhibitor | 0.72 | 0.32-1.64 | 0.433 |
| Oral anticoagulation | 1.38 | 0.87-2.19 | 0.166 |
| β-blockers | 0.86 | 0.59-1.27 | 0.444 |
| ACEI/ARB | 0.70 | 0.48-1.02 | 0.065 |
| Calcium channel blockers  | 1.36 | 0.83-2.23 | 0.219 |
| Nitrates | 1.23 | 0.62-2.44 | 0.561 |
| Diuretics | 1.96 | 1.29-2.97 | 0.001 |
| Statins | 0.71 | 0.48-1.03 | 0.074 |
| Anxiolytic medication | 1.14 | 0.75-1.72 | 0.540 |
| Antidepressant therapy | 1.46 | 0.86-2.48 | 0.165 |
| ACEI/ARB: Angiotensin-Converting enzyme inhibitors (ACEI) and angiotensin receptor blockers; CI: Confidence Interval; COPD: Chronic Obstructive Pulmonary Disease; HR: Hazard Ratio. |

|  |
| --- |
| Table 2. Baseline characteristics after propensity score matching according to the prescription of β-blockers. |
| Variables | **β-blockers****(n=202)** | **Non β-blockers****(n=202)** | **SMD** |
| Age | 70.4 ± 11.9 | 70.8 ± 12.4 | -0.033 |
| Female sex | 523 (89.9%) | 331 (85.3%) | 0.016 |
|  *Smoking* | 66 (11.3%) | 59 (15.2%) | 0.047 |
|  *Hypertension* | 393 (67.5%) | 235 (60.6%) | 0.042 |
|  *Dyslipemia* | 272 (46.7%) | 172 (44.3%) | -0.069 |
|  *Diabetes mellitus* | 112 (19.2%) | 72 (18.6%) | -0.050 |
|  *Peripheral artery disease* | 22 (3.8%) | 10 (2.6%) | 0.078 |
|  *Coronary artery disease* | 40 (6.9%) | 30 (7.7%) | 0.020 |
|  *Prior stroke* | 50 (8.6%) | 20 (5.2%) | 0.124 |
| Prior β-blocker therapy | 72 (12.4%) | 19 (4.9%) | 0.190 |
| Comorbidities |  |  |  |
|  *COPD* | 69 (11.9%) | 80 (20.6%) | -0.092 |
|  *History of cancer* | 54 (9.3%) | 54 (13.9%) | -0.017 |
| Presenting characteristics |  |  |  |
|  *Killip ≥ II at admission* | 176 (30.2%) | 142 (36.6%) | -0.129 |
|  *Atrial fibrillation/flutter* | 104 (17.9%) | 68 (17.5%) | -0.065 |
|  *Bundle brunch block* | 38 (6.5%) | 16 (4.1%) | 0.120 |
|  *Creatinine > 1.5 mg/dL* | 35 (6.0%) | 12 (3.1%) | 0.042 |
| Treatment at discharge |  |  |  |
|  *Aspirin* | 329 (56.5%) | 125 (32.2%) | 0.020 |
|  *P2Y12 inhibitor* | 49 (8.4%) | 18 (4.6%) | 0.053 |
|  *Oral anticoagulation* | 117 (20.1%) | 49 (12.6%) | 0.086 |
|  *ACEI/ARB* | 426 (73.2%) | 168 (43.3%) | -0.056 |
|  *Calcium channel blockers*  | 38 (6.5%) | 47 (12.1%) | -0.080 |
|  *Nitrates* | 21 (3.6%) | 14 (3.6%) | -0.053 |
|  *Diuretics* | 147 (25.3%) | 80 (20.6%) | 0.011 |
|  *Statins* | 345 (59.3%) | 132 (34.0%) | 0.131 |
|  *Anxiolytic medication* | 187 (32.1%) | 81 (20.9%) | 0.021 |
|  *Antidepressant therapy* | 90 (15.5%) | 40 (10.3%) | 0.027 |
| Values are mean ± standard difference or %. ACEI/ARB: Angiotensin-Converting enzyme inhibitors (ACEI) and angiotensin receptor blockers; COPD: Chronic Obstructive Pulmonary Disease; SMD: Standardized Mean Difference. |